Ribavirin-pegylated interferon alfa induction hcv combination therapy

摘要: The use of ribavirin and interferon alpha for the manufacture pharmaceutical compositions treating a patient having chronic hepatitis C infection, e.g., HCV genotype 1, 2 or 3, to eradicate detectable HCV-RNA by method comprising administering an effective amount in association with pegylated alpha, characterised that patients infections is effected two treatment time periods: (a) first period at least 20 30 wherein therapeutically induction dosing interferon-alfa, interferon-alfa-2b sufficient substantially lower, preferably eradicate, HCV-RNA, are administered; (b) second weeks interferon-alfa administered maintian no 20-30 after end maintain 24 disclosed.